Haynes and Boone Represents VBI Vaccines in Financings for Gross Proceeds of $71.9 Million
October, 2017 - Dallas, Texas
Haynes and Boone, LLP represented client VBI Vaccines Inc. in its successful underwritten public offering and concurrent registered direct offering of common shares for aggregate gross proceeds of approximately $71.9 million.
Partner Rick Werner led the Haynes and Boone team representing VBI, assisted by Associates Jayun Koo and Pat Horan.
VBI Vaccines (Nasdaq: VBIV), based in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, such as vaccines to prevent hepatitis B (HBV), cytomegalovirus (CMV) and glioblastoma multiforme (GBM).
BMO Capital Markets and Canaccord Genuity acted as book-runners, and Ladenburg Thalmann acted as lead manager for the underwritten public offering.
Haynes and Boone is one of The American Lawyer top 100 law firms, with more than 600 lawyers in 15 offices and 40 major legal practices. We are among the largest firms based in the United States. Our growth has been driven by our client service strengths, especially our problem-solving acumen and ability to collaborate with clients.
